Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab IV versus adalimumab SC for moderately to severely active ulcerative colitis
NL-OMON43558Phase 3Active, not recruiting
- Sponsor
- Takeda
- Start
- Jan 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis and inflammatory bowel disease (IBD) comparing Vedolizumab arm with Adalimumab arm (2 arms). Primary endpoint: Clinical remission at Week 52. Started Jan 2016; status: active, not recruiting.
02
Drugs
vedolizumabadalimumab
03
Conditions
autoimmune colitisinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NL-OMON43558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43558.